Synapse

← Oncolytic Virotherapy

Papers in Oncolytic Virotherapy

Page 1 · newest first

  1. The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma TreatmentOncolytic Virotherapy · 2021
  2. Treatment of an Alveolar Rhabdomyosarcoma Allograft with Recombinant Myxoma Virus and OclacitinibOncolytic Virotherapy · 2020
  3. Virus–Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus DevelopmentOncolytic Virotherapy · 2020
  4. Virus–Receptor Interactions: Structural Insights For Oncolytic Virus DevelopmentOncolytic Virotherapy · 2019
  5. Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant GliomaOncolytic Virotherapy · 2019
  6. Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypesOncolytic Virotherapy · 2019
  7. Development and applications of oncolytic Maraba virus vaccinesOncolytic Virotherapy · 2018
  8. Oncolytic myxoma virus synergizes with standard of care for treatment of glioblastoma multiformeOncolytic Virotherapy · 2018
  9. Oral poliovirus vaccine-induced programmed cell death involves both intrinsic and extrinsic pathways in human colorectal cancer cellsOncolytic Virotherapy · 2018
  10. Three-dimensional tumor cell cultures employed in virotherapy researchOncolytic Virotherapy · 2018
  11. Oncolytic virus and PD-1/PD-L1 blockade combination therapyOncolytic Virotherapy · 2018
  12. Current understanding of reovirus oncolysis mechanismsOncolytic Virotherapy · 2018
  13. Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancerOncolytic Virotherapy · 2018
  14. Oncolytic virotherapy in upper gastrointestinal tract cancersOncolytic Virotherapy · 2018
  15. The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic virusesOncolytic Virotherapy · 2018
  16. Potential of oncolytic viruses in the treatment of multiple myelomaOncolytic Virotherapy · 2018
  17. Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effectOncolytic Virotherapy · 2017
  18. Proinflammatory response induced by Newcastle disease virus in tumor and normal cellsOncolytic Virotherapy · 2017
  19. Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunityOncolytic Virotherapy · 2017
  20. Editorial announcing PubMed indexing of Oncolytic VirotherapyOncolytic Virotherapy · 2017
  21. Oncolytic virotherapy including Rigvir and standard therapies in malignant melanomaOncolytic Virotherapy · 2017
  22. Novel oncolytic viral therapies in patients with thoracic malignanciesOncolytic Virotherapy · 2016
  23. CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapterOncolytic Virotherapy · 2016
  24. Oncolytic Seneca Valley Virus: past perspectives and future directionsOncolytic Virotherapy · 2016
  25. Myxoma virus therapy of human embryonal rhabdomyosarcoma in a nude mouse modelOncolytic Virotherapy · 2016
  26. Oncolytic adenovirus-mediated therapy for prostate cancerOncolytic Virotherapy · 2016
  27. Thyroid malignancy neoplasm-associated biomarkers as targets for oncolytic virotherapyOncolytic Virotherapy · 2016
  28. High-throughput screening to enhance oncolytic virus immunotherapyOncolytic Virotherapy · 2016
  29. Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesOncolytic Virotherapy · 2016
  30. Combining HDAC inhibitors with oncolytic virotherapy for cancer therapyOncolytic Virotherapy · 2015
  31. Targeting tumor vasculature through oncolytic virotherapy: recent advancesOncolytic Virotherapy · 2015
  32. Oncolytic virotherapy using herpes simplex virus: how far have we come?Oncolytic Virotherapy · 2015
  33. Ultrasound-mediated oncolytic virus delivery and uptake for increased therapeutic efficacy: state of artOncolytic Virotherapy · 2015
  34. Oncolytic Sendai virus-based virotherapy for cancer: recent advancesOncolytic Virotherapy · 2015
  35. Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technologyOncolytic Virotherapy · 2015
  36. Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapyOncolytic Virotherapy · 2015
  37. Characterization of an oncolytic adenovirus vector constructed to target the cMet receptorOncolytic Virotherapy · 2015
  38. Oncolytic virotherapy for human malignant mesothelioma: recent advancesOncolytic Virotherapy · 2015
  39. Advances in the design and development of oncolytic measles virusesOncolytic Virotherapy · 2015
  40. On the potential of oncolytic virotherapy for the treatment of canine cancersOncolytic Virotherapy · 2015
  41. Oncolytic virotherapy for head and neck cancer: current research and future developmentsOncolytic Virotherapy · 2015
  42. Promising oncolytic agents for metastatic breast cancer treatmentOncolytic Virotherapy · 2015
  43. Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapyOncolytic Virotherapy · 2015
  44. Therapeutic potential of oncolytic Newcastle disease virus a critical reviewOncolytic Virotherapy · 2015
  45. Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapyOncolytic Virotherapy · 2015
  46. The ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implicationsOncolytic Virotherapy · 2015
  47. Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapyOncolytic Virotherapy · 2015
  48. The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)Oncolytic Virotherapy · 2015
  49. Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor–resistant multiple myelomaOncolytic Virotherapy · 2015
  50. Immune cells: more than simple carriers for systemic delivery of oncolytic virusesOncolytic Virotherapy · 2014